Key Lab for Microorganisms and Biotransformation, South-Central University for Nationalities, No. 708, Minyuan Road, Hongshan District, Wuhan City, Hubei Province, 430074, China.
Antonie Van Leeuwenhoek. 2012 Nov;102(4):561-8. doi: 10.1007/s10482-012-9751-x. Epub 2012 May 24.
To test the in vivo benefits of three lactobacilli and to compare their different efficacies based on strain-specific activities by using rats as an experimental model, a growth-promotion and a challenge trial were conducted. The three strains, Lactobacillus salivarius G1-1, Lactobacillus reuteri G22-2, and Lactobacillus reuteri G8-5 shared antimicrobial, bile-salt-hydrolase and amylolytic activities in vitro, respectively. In the 17 day growth-promotion trial, 48 rats were allotted to four treatments with 12 replicates per treatment: a control group, which received saline, as well as three experimental groups, which received 10(8) cells/ml of one of the three lactobacilli in saline suspension. The results showed that compared with the control group, L. reuteri G8-5 significantly improved feed efficiency and decreased fecal pH values on days 8 and 17, concomitant with reduced faecal coliform counts on d 17 (p < 0.05). All treatments with lactobacilli caused an increase in the moisture content of the faeces and a decrease in the serum total cholesterol and blood urea nitrogen levels. High-density lipoprotein cholesterol was only elevated for rats which received L. reuteri G22-2. In the Salmonella-challenge trial, 40 rats were allotted to five treatments (8 replicates per treatment) which consisted of a positive control (infected, no Lactobacillus pretreatment), a negative control (uninfected, no Lactobacillus pretreatment) and three Lactobacillus-pretreated groups (10(9) cells/ml in saline). The results showed that rats in all Lactobacillus pretreated groups were protected from infection with significantly higher weight gain, feed intake and feed efficiency compared with positive control rats (p < 0.05). Rats treated with L. salivarius G1-1 and L. reuteri G22-2 tended to exhibit higher weight gains than those pretreated with L. reuteri G8-5. Significantly lower Salmonella shedding in faeces, Salmonella numbers in the spleen and the relative weight of the spleen were observed in the Lactobacillus groups (p < 0.05). Based on the overall results, it can be concluded that not all strains within the same lactobacilli species show similar effects and that some of the beneficial functionalities to animals were strain-specific. Therefore strains for practical application need to be carefully selected based on their strain-specific characters.
为了测试三种乳酸菌的体内益处,并基于菌株特异性活性比较它们的不同功效,我们使用大鼠作为实验模型进行了促生长和攻毒试验。这三种菌株分别是唾液乳杆菌 G1-1、罗伊氏乳杆菌 G22-2 和罗伊氏乳杆菌 G8-5,它们在体外具有抗菌、胆汁盐水解酶和淀粉水解活性。在 17 天的促生长试验中,将 48 只大鼠分为四组,每组 12 个重复:对照组,给予生理盐水;三个实验组,分别给予生理盐水悬液中 10(8)cfu/ml 的三种乳酸菌之一。结果表明,与对照组相比,L. reuteri G8-5 显著提高了饲料效率,并降低了第 8 天和第 17 天的粪便 pH 值,同时降低了第 17 天的粪便大肠菌群数量(p<0.05)。所有使用乳酸菌的处理都导致粪便的水分含量增加,血清总胆固醇和血尿素氮水平降低。只有接受 L. reuteri G22-2 处理的大鼠高密度脂蛋白胆固醇升高。在沙门氏菌攻毒试验中,将 40 只大鼠分为五组(每组 8 个重复),包括阳性对照组(感染,无乳酸菌预处理)、阴性对照组(未感染,无乳酸菌预处理)和三个乳酸菌预处理组(生理盐水 10(9)cfu/ml)。结果表明,与阳性对照组相比,所有接受乳酸菌预处理的大鼠均受到感染保护,体重增加、采食量和饲料效率显著提高(p<0.05)。与接受 L. reuteri G8-5 预处理的大鼠相比,接受 L. salivarius G1-1 和 L. reuteri G22-2 处理的大鼠体重增加趋势更高。在乳酸菌组中,粪便中沙门氏菌脱落量、脾脏中的沙门氏菌数量和脾脏相对重量显著降低(p<0.05)。基于总体结果,可以得出结论,并非同一乳杆菌属内的所有菌株都表现出相似的效果,并且一些对动物有益的功能是菌株特异性的。因此,需要根据菌株特异性特征仔细选择实际应用的菌株。